

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for June 2024

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Levofloxacin	Levaquin	LEVOFLOXACIN HEMIHYDRATE	750 mg	tablet	02508478
Sandoz Canada Inc.	Sandoz Lisdexamfetamine Capsules	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	70 mg	capsule	02546302
Teva Canada Limited	Teva- Lisdexamfetamine	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	70 mg	capsule	02545942
Sanis Health Inc.	Sildenafil	Viagra	SILDENAFIL	25 mg	tablet	02540770